Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Ravi A Madan et al.   LANCET ONCOLOGY

Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research

(2011) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

(2009) James L. Gulley et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY